Researchers have identified new drug candidates that could help the immune system detect HIV-infected cells by targeting the protein Nef, which allows the cells to evade detection. These drug candidates, called PROTACs, could potentially unmask the reservoir of dormant HIV-infected cells that current antiretroviral therapy cannot clear. While the discovery has generated excitement, further research and preclinical testing in animal models are needed before potential clinical trials can be pursued.
Scientists have developed two new drug candidates inspired by the traditional African psychedelic plant medicine ibogaine, which have the potential to treat addiction and depression. These compounds target the serotonin transporter and mimic ibogaine's desirable effects without its dangerous side effects. Initial testing in mice has shown promising results, and further research is underway to explore their therapeutic potential. The new molecules are more powerful than SSRI antidepressants and could offer a safer and more effective treatment option for patients suffering from addiction and depression.
